Bruce Frazier Bayer Pharmaceuticals

Bruce joined Bayer’s Product Supply division in 2022 to lead the implementation of a new contract service offering within Biotech@Bayer. Based out of the Berkeley CA facility, he is responsible for oversight of a global team supporting the establishment of the business and service components as well as acquisition of external projects. The program was officially launched as BioPartnering SolutionsTM in early 2023, with the goal of providing innovators access to Bayer’s global network of CMC development and manufacturing capabilities, enabling them to deliver new therapies to patients and also exemplifying Bayer’s commitment to its vision of “Health For All”. Prior to this role, Bruce was VP of Business Development and Sales for Bionova Scientific, where he helped lead the expansion of the company from a contract development/analytical testing provider into a full-service CDMO, ultimately resulting in its acquisition by Asahi-Kasei.

Bruce started his 20+ year career in the Biotech industry with a mAb/ADC developer that evolved into a CMO. This provided in-depth experience on both sides of the contract testing and manufacturing business, and it enabled him to contribute in a variety of roles of increasing responsibility with industry leading CROs and CDMOs that included sales, business development, account management, site leadership and business strategy. Bruce has experience in leadership and strategy with both small and large organizations, providing services spanning the full product life cycle from preclinical development to clinical and commercial supply, across multiple modalities, with an increased focus on cell and gene therapies in his current role with Bayer.